Pharma Capital

Faron Pharmaceuticals' Markku Jalkanen 'excited' to be advancing Clevegen

Markku Jalkanen, chief executive of clinical stage biopharma group Faron Pharmaceuticals Oy (LON:FARN) tells Proactive he's hugely excited to be teaming up with the University of Birmingham as they look to advance their potential cancer immunotherapy, Clevegen.

 

View full FARN profile

Faron Pharmaceuticals Oy Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.